|
|
News Breaks | | | | December 4, 2012 | | 13:04 EDT |  | ENMD | EntreMed announces publication of preclinical results for MS treatment
EntreMed announced that preclinical results for its compound 2-methoxyestradiol, 2ME2, were published on line in this week's Early Edition of Proceedings of the National Academy of Sciences. The study was conducted at The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital and was led by Tak W. Mak, Ph.D., who commented on the study: "There exists significant unmet medical need for safe and effective drugs to treat MS. In this study, we demonstrated that 2ME2, an endogenous metabolite of estradiol, significantly inhibits lymphocyte activation and proliferation and dramatically suppresses development of experimental MS...The study provides for the first time a molecular rational for the use of 2ME2 as a tolerable oral immunomodulatory agent for autoimmune disorders such as MS...We believe that 2ME2 may offer a safe and effective treatment for such autoimmune disorders." | |
|
News For ENMD From The Last 14 Days Check below for free stories on ENMD the last two weeks. |
|
|
| There are no results for ENMD |
|
|
|
|
|
|
